Zivo Bioscience (ZIVO) AI Stock Analysis

• Market Cap: $63.91M
• Dividend Yield: N/A
• Average Volume (3M): 349.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: 398.55%
• EPS Growth: 8.27%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -4.35
• Shares Outstanding: 3,759,213
• 10 Day Avg. Volume: 262
• 30 Day Avg. Volume: 349
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 408.87
• Price to Cash Flow (P/CF): -17.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company's negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.

Positive Factors

Licensing Agreements

ZIVO is engaged in constructive discussions with two major global animal health companies regarding potential licensing agreements for ZIVO’s coccidiosis product.

Product Development

Positive results from the avian flu study and plans for an additional trial are viewed favorably as it could expand ZIVO’s opportunities in poultry health.

Negative Factors

Capital Challenges

Ongoing challenges of raising capital as an unlisted security is a concern.

Financial Health

There is a risk that a deal does not come to fruition, combined with lingering concerns regarding the balance sheet and access to capital.

Zivo Bioscience Business Overview & Revenue Model

Company Description

Zivo Bioscience (ZIVO) is a biotechnology company focused on the research and development of natural bioactive compounds derived from its proprietary algal cultures. The company operates primarily in the sectors of health and wellness, animal nutrition, and functional food ingredients. Zivo's main products include algal-derived compounds that are designed to improve health outcomes in both humans and animals through enhanced nutrition and immune support.

How the Company Makes Money

Zivo Bioscience makes money by developing and licensing its proprietary algal bioactive compounds to companies in the nutrition, wellness, and animal health industries. The company's revenue streams largely consist of licensing fees, royalties, and collaborative research agreements. Through partnerships with manufacturers and distributors, Zivo capitalizes on its intellectual property by integrating its algal compounds into various consumer and animal products. The company may also engage in direct sales of its algal biomass or extracts to businesses looking to include these components in their product offerings. Key partnerships in these sectors help Zivo expand its market reach and contribute to its earnings.

Zivo Bioscience Financial Statement Overview

Summary

Zivo Bioscience is experiencing growth in revenue but is struggling with significant net losses and negative cash flows, indicating financial instability. The balance sheet reflects insolvency with negative equity, requiring urgent financial restructuring. The biotech industry is inherently risky, and the company needs to address its financial challenges to achieve sustainability.

Income Statement

Zivo Bioscience has shown revenue growth over the years, with a TTM revenue of $79,020 compared to $27,650 in the previous year, indicating a significant growth trajectory. However, the company continues to report substantial net losses, resulting in a negative net profit margin. The EBIT and EBITDA margins are negative, reflecting ongoing operational challenges and a lack of profitability.

Balance Sheet

The company's balance sheet is weak with a negative stockholders' equity, indicating insolvency. The debt-to-equity ratio cannot be accurately calculated due to negative equity. The equity ratio is negative due to liabilities exceeding assets, highlighting significant financial risk.

Cash Flow

Zivo Bioscience's cash flow statement reveals a consistent pattern of negative free cash flow, impacting liquidity. The operating cash flow to net income ratio is negative, showing poor cash generation relative to net losses. Although financing activities have provided some cash inflow, it is insufficient to cover operating cash outflows.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
79.02K	27.65K	0.00	0.00	20.00K	0.00
	Gross Profit
26.08K	11.61K	0.00	0.00	20.00K	0.00
	EBIT
-13.66M	-7.26M	-8.73M	-9.05M	-8.56M	-8.35M
	EBITDA
-13.66M	-7.26M	-8.73M	-9.05M	-550.05K	-8.35M
	Net Income Common Stockholders
-13.69M	-7.78M	-8.75M	-9.40M	-9.66M	-14.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
388.89K	274.38K	1.80M	8.90M	137.86K	346.11K
	Total Assets
411.51K	555.72K	2.12M	8.99M	220.18K	369.39K
	Total Debt
18.15M	346.34K	445.18K	255.18K	5.36M	5.28M
	Net Debt
17.77M	71.96K	-1.35M	-8.65M	5.22M	4.93M
	Total Liabilities
22.69M	2.76M	2.13M	2.95M	11.53M	8.71M
	Stockholders Equity
-22.28M	-2.21M	-10.62K	6.04M	-11.31M	-8.34M
Cash Flow		Free Cash Flow
-4.12M	-5.80M	-7.10M	-6.80M	-2.59M	-3.71M
	Operating Cash Flow
-4.12M	-5.80M	-7.10M	-6.80M	-2.59M	-3.71M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
2.80M	4.28M	-628.60K	15.57M	2.38M	3.66M

Zivo Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZIVO, the sentiment is Negative. The current price of 15 is below the 20-day moving average (MA) of 16.94, below the 50-day MA of 18.53, and below the 200-day MA of 16.15, indicating a bearish trend. The MACD of -0.54 indicates Positive momentum. The RSI at 44.76 is Neutral, neither overbought nor oversold. The STOCH value of 44.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZIVO.

Zivo Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
SNGX	43 Neutral	$5.96M	―	-248.97%	―	―	57.83%
CTXR	42 Neutral	$8.99M	―	-52.85%	―	―	8.99%
ZIVO	34 Underperform	$63.91M	―	657.30%	―	398.55%	8.27%
OTLK	28 Underperform	$40.45M	―	<0.01%	―	―	-29.01%